To include your compound in the COVID-19 Resource Center, submit it here.

Galapagos reports Phase II CF data for GLPG2222 combo

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said cystic fibrosis candidate GLPG2222 plus Kalydeco ivacaftor significantly reduced sweat chloride levels vs. placebo plus Kalydeco in the Phase II ALBATROSS trial. The double-blind, international trial enrolled 37

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers